Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28704410 | 0.79 | — | — | |
| SCHEMBL4196098 | 0.72 | — | — | |
| SCHEMBL4031965 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL8667532 | 0.71 | GAA (0.41) | LMNAMGAMGAASIMGAM2 | |
| SCHEMBL10698265 | 0.71 | — | — | |
| SCHEMBL4030697 | 0.68 | MGAM (0.33) | LMNAMGAMGAASIMGAM2 | |
| SCHEMBL4030693 | 0.68 | MGAM (0.33) | LMNAMGAMGAASIMGAM2 | |
| SCHEMBL11791555 | 0.64 | MGAM (0.32) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL3752510 | 0.63 | — | — | |
| SCHEMBL3752512 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560593-B2 | Process for producing nitroisourea derivatives | MITSUI CHEMICALS, INC. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20090018363-A1 | PROCESS FOR PRODUCING NITROISOUREA DERIVATIVES | MITSUI CHEMICALS, INC (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1985610-A1 | IMPROVED METHOD FOR PRODUCING NITROISOUREA DERIVATIVE | Mitsui Chemicals, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018363-A1 | PROCESS FOR PRODUCING NITROISOUREA DERIVATIVES | NOS2, NOS1, NIT2 | LMNA 4340/4885MGAM 134/4885GAA 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.